Kenvue rises in early trading, reversing some of yesterday’s drop, as scientists push back on Tylenol-autism link
Kenvue, the company behind pain relief medication Tylenol, is seeing shares rebound a little this morning as doctors push back against President Trump’s claims about the drug’s link to autism, per Reuters.
At a news conference yesterday, the president repeatedly warned pregnant women to avoid taking Tylenol, suggesting that the drug’s active ingredient (acetaminophen) is connected to rising autism rates in the US, sending shares in Kenvue, which was spun off from Johnson & Johnson just over two years ago, slumping to a record low.
A company spokesperson has since rejected the claims, scientists have started weighing in, and the FDA has confirmed that, while it will change warning labels on drugs containing acetaminophen, a causal relationship has not been established.
The company’s stock was up about 6% in premarket trading as of 6:20 a.m. ET.